Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C9H9NO |
| Molecular Weight | 147.1739 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OCC1=CNC2=C1C=CC=C2
InChI
InChIKey=IVYPNXXAYMYVSP-UHFFFAOYSA-N
InChI=1S/C9H9NO/c11-6-7-5-10-9-4-2-1-3-8(7)9/h1-5,10-11H,6H2
Indole-3-carbinol (I3C), a common phytochemical in cruciferous vegetables, and its condensation product, 3,3'-diindolylmethane (DIM) exert several biological activities on cellular and molecular levels, which contribute to their well-recognized chemoprevention potential. ndole-3-carbinol is used for prevention of breast cancer, colon cancer, and other types of cancer. The National Institutes of Health (NIH) has reviewed indole-3-carbinol as a possible cancer preventive agent and is now sponsoring clinical research for breast cancer prevention. Indole-3-carbinol is also used for fibromyalgia, tumors inside the voice box (laryngeal papillomatosis) caused by a virus, tumors inside the respiratory tract (respiratory papillomatosis) caused by a virus, abnormal cell growth in the cervix (cervical dysplasia), and systemic lupus erythematosus (SLE). Indole-3-carbinol scavenges free radicals and induces various hepatic cytochrome P450 monooxygenases. Specifically, this agent induces the hepatic monooxygenase cytochrome P4501A1 (CYP1A1), resulting in increased 2-hydroxylation of estrogens and increased production of the chemoprotective estrogen 2-hydroxyestrone. Accumulating
evidence indicates that the antitumor activity of indole-3-
carbinol is attributable to its ability to interfere with multiple
oncogenic signaling pathways governing cell cycle progression,
survival, invasion, and other aggressive phenotypes of
cancer cells. Reported signaling targets of indole-3-
carbinol in various cancer cell lines include EGFR/Src,
Akt/NF-B, stress responses, elastase,
and Rho kinase. Moreover, indole-3-carbinol functions
as a negative regulator of estrogen action in hormonesensitive
cancer cells through the inhibition of estrogen receptor
(ER)-alpha signaling and/or induction of cytochrome
P-450-mediated estrogen metabolism, suggesting
its clinical use in hormone-sensitive cancers.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: P46934|||D6RF89 Gene ID: 4734.0 Gene Symbol: NEDD4 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/27979631 |
284.0 µM [IC50] | ||
Target ID: CHEMBL3201 |
|||
Target ID: CHEMBL4506 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22986685 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Preventing | Unknown Approved UseUnknown |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
262 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17164373 |
800 mg single, oral dose: 800 mg route of administration: Oral experiment type: SINGLE co-administered: |
3,3'-DIINDOLYLMETHANE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
510 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17164373 |
1200 mg single, oral dose: 1200 mg route of administration: Oral experiment type: SINGLE co-administered: |
3,3'-DIINDOLYLMETHANE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
61 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17164373/ |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
3,3'-DIINDOLYLMETHANE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
69 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17164373/ |
400 mg 2 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
3,3'-DIINDOLYLMETHANE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
607 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17164373/ |
1000 mg single, oral dose: 1000 mg route of administration: Oral experiment type: SINGLE co-administered: |
3,3'-DIINDOLYLMETHANE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
93 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17164373/ |
600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered: |
3,3'-DIINDOLYLMETHANE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
1608 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17164373 |
800 mg single, oral dose: 800 mg route of administration: Oral experiment type: SINGLE co-administered: |
3,3'-DIINDOLYLMETHANE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
3212 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17164373 |
1200 mg single, oral dose: 1200 mg route of administration: Oral experiment type: SINGLE co-administered: |
3,3'-DIINDOLYLMETHANE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
329 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17164373/ |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
3,3'-DIINDOLYLMETHANE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
372 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17164373/ |
400 mg 2 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
3,3'-DIINDOLYLMETHANE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
3376 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17164373/ |
1000 mg single, oral dose: 1000 mg route of administration: Oral experiment type: SINGLE co-administered: |
3,3'-DIINDOLYLMETHANE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
364 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17164373/ |
600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered: |
3,3'-DIINDOLYLMETHANE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
4.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17164373 |
800 mg single, oral dose: 800 mg route of administration: Oral experiment type: SINGLE co-administered: |
3,3'-DIINDOLYLMETHANE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17164373 |
1200 mg single, oral dose: 1200 mg route of administration: Oral experiment type: SINGLE co-administered: |
3,3'-DIINDOLYLMETHANE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
3.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17164373/ |
400 mg single, oral dose: 400 mg route of administration: Oral experiment type: SINGLE co-administered: |
3,3'-DIINDOLYLMETHANE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17164373/ |
400 mg 2 times / day multiple, oral dose: 400 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
3,3'-DIINDOLYLMETHANE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
5.7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17164373/ |
1000 mg single, oral dose: 1000 mg route of administration: Oral experiment type: SINGLE co-administered: |
3,3'-DIINDOLYLMETHANE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
|
2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17164373/ |
600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered: |
3,3'-DIINDOLYLMETHANE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE food status: FASTED |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Indole-3-carbinol stimulates transcription of the interferon gamma receptor 1 gene and augments interferon responsiveness in human breast cancer cells. | 2004-07 |
|
| Indole-3-carbinol for recurrent respiratory papillomatosis: long-term results. | 2004-06 |
|
| Effects of cruciferous vegetable consumption on urinary metabolites of the tobacco-specific lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in singapore chinese. | 2004-06 |
|
| Effects of dietary anticarcinogens and nonsteroidal anti-inflammatory drugs on rat gastrointestinal UDP-glucuronosyltransferases. | 2004-05-27 |
|
| Inhibition of MUC1 expression by indole-3-carbinol. | 2004-05-10 |
|
| Modulation of the constitutive activated STAT3 transcription factor in pancreatic cancer prevention: effects of indole-3-carbinol (I3C) and genistein. | 2004-03-16 |
|
| Endogenous and dietary indoles: a class of antioxidants and radical scavengers in the ABTS assay. | 2004-03 |
|
| Lack of an inducible effect of dietary soy isoflavones on the mRNA abundance of hepatic cytochrome P-450 isozymes in rats. | 2004-03 |
|
| Cruciferous vegetables: cancer protective mechanisms of glucosinolate hydrolysis products and selenium. | 2004-03 |
|
| Established and potential strategies against papillomavirus infections. | 2004-02 |
|
| Differences in the hepatic P450-dependent metabolism of estrogen and tamoxifen in response to treatment of rats with 3,3'-diindolylmethane and its parent compound indole-3-carbinol. | 2004 |
|
| Indole-3-carbinol induces a G1 cell cycle arrest and inhibits prostate-specific antigen production in human LNCaP prostate carcinoma cells. | 2003-12-01 |
|
| Broccoli compound inhibits HSV. | 2003-11 |
|
| A selective irreversible inhibitor targeting a PDZ protein interaction domain. | 2003-10-08 |
|
| Ingestion of a dietary supplement containing dehydroepiandrosterone (DHEA) and androstenedione has minimal effect on immune function in middle-aged men. | 2003-10 |
|
| Chemoprevention of gastrointestinal malignancies. | 2003-09 |
|
| Effects of treatment of rats with indole-3-carbinol on apoptosis in the mammary gland and mammary adenocarcinomas. | 2003-08-05 |
|
| The disposition and metabolism of 2-amino-3-methylimidazo-[4,5-f]quinoline in the F344 rat at high versus low doses of indole-3-carbinol. | 2003-08 |
|
| Evaluation of chronic dietary exposure to indole-3-carbinol and absorption-enhanced 3,3'-diindolylmethane in sprague-dawley rats. | 2003-07 |
|
| Arsenate reduction in human erythrocytes and rats--testing the role of purine nucleoside phosphorylase. | 2003-07 |
|
| Plant-derived 3,3'-Diindolylmethane is a strong androgen antagonist in human prostate cancer cells. | 2003-06-06 |
|
| Pretreatment of indole-3-carbinol augments TRAIL-induced apoptosis in a prostate cancer cell line, LNCaP. | 2003-06-05 |
|
| Indole-3-carbinol and 3,3'-diindolylmethane induce apoptosis in human prostate cancer cells. | 2003-06 |
|
| Cervical dysplasia: early intervention. | 2003-05 |
|
| Phase II in vitro metabolism of 3-methylindole metabolites in porcine liver. | 2003-05 |
|
| Liquid chromatographic assay for the simultaneous determination of indole-3-carbinol and its acid condensation products in plasma. | 2003-04-25 |
|
| Mutational analysis of Ctnnb1 and Apc in tumors from rats given 1,2-dimethylhydrazine or 2-amino-3-methylimidazo[4,5-f]quinoline: mutational 'hotspots' and the relative expression of beta-catenin and c-jun. | 2003-04 |
|
| Beneficial and adverse effects of chemopreventive agents. | 2003-03-12 |
|
| Mechanism-based in vitro screening of potential cancer chemopreventive agents. | 2003-03-12 |
|
| Chemoprevention of colon cancer by Korean food plant components. | 2003-03-12 |
|
| A high-throughput cell-based reporter gene system for measurement of CYP1A1 induction. | 2003-03-12 |
|
| The effect of indole-3-carbinol and sulforaphane on a prostate cancer cell line. | 2003-03 |
|
| The rainbow trout (Oncorhynchus mykiss) tumor model: recent applications in low-dose exposures to tumor initiators and promoters. | 2003-02-25 |
|
| Anti-metastatic activities of all-trans retinoic acid, indole-3-carbinol and (+)-catechin in Dunning rat invasive prostate adenocarcinoma cells. | 2003-01-30 |
|
| Modulation of vinca-alkaloid induced P-glycoprotein expression by indole-3-carbinol. | 2003-01-28 |
|
| Growth-inhibitory effects of the chemopreventive agent indole-3-carbinol are increased in combination with the polyamine putrescine in the SW480 colon tumour cell line. | 2003-01-14 |
|
| Convenient synthesis of 5,6,11,12,17,18- hexahydrocyclononal[1,2-b:4,5-b':7,8-b'']triindole, a novel phytoestrogen. | 2003-01-10 |
|
| Role of salicylic acid in systemic resistance induced by Pseudomonas fluorescens against Fusarium oxysporum f. sp. ciceri in chickpea. | 2003 |
|
| Chapter 17: Genital human papillomavirus infections--current and prospective therapies. | 2003 |
|
| Indole-3-carbinol (I3C) induces apoptosis in tumorigenic but not in nontumorigenic breast epithelial cells. | 2003 |
|
| Antigenotoxic potential of certain dietary constituents. | 2003 |
|
| Differential effects of vegetable-derived indoles on the induction of quinone reductase in hepatoma cells. | 2002-12 |
|
| Plant-derived biomolecules in fermented cabbage. | 2002-11-06 |
|
| Indole-3-carbinol inhibits protein kinase B/Akt and induces apoptosis in the human breast tumor cell line MDA MB468 but not in the nontumorigenic HBL100 line. | 2002-11 |
|
| Why phase II trials in cervical chemoprevention are negative: what have we learned? | 2002-11 |
|
| Further investigation of the modifying effect of various chemopreventive agents on apoptosis and cell proliferation in human colon cancer cells. | 2002-10 |
|
| Development of a multi-organ rat model for evaluating chemopreventive agents: efficacy of indole-3-carbinol-. Certain health supplements may cause both carcinogenic and anticarcinogenic effects. | 2002-10 |
|
| Endocrine disruption by indole-3-carbinol and tamoxifen: blockage of ovulation. | 2002-09-15 |
|
| Multiple molecular targets of indole-3-carbinol, a chemopreventive anti-estrogen in breast cancer. | 2002-08 |
|
| Lack of chemoprevention of indole-3-carbinol in N-methyl-N-nitrosourea-induced mammary carcinogenesis in rats. | 2002 |
Patents
Sample Use Guides
For treating abnormal cells on the surface of the cervix (cervical dysplasia): 200-400 mg per day has been used. However, 200 mg seems to be as effective as the higher dose.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3556531
Curator's Comment: Treating MCF-7 cells with 100 uM Indole-3-carbinol reduced ER-α mRNA expression by approximately 60%. https://www.ncbi.nlm.nih.gov/pubmed/16488130compared to controls.
Using mouse liver microsomes in an NADPH-fortified reaction mixture, Indole-3-carbinol inhibited, in a concentration-dependent manner, CCl4-initiated lipid peroxidation, with 50% inhibition at 35-40 uM Indole-3-carbinol.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
DSLD |
473 (Number of products:104)
Created by
admin on Mon Mar 31 18:00:39 GMT 2025 , Edited by admin on Mon Mar 31 18:00:39 GMT 2025
|
||
|
NCI_THESAURUS |
C68534
Created by
admin on Mon Mar 31 18:00:39 GMT 2025 , Edited by admin on Mon Mar 31 18:00:39 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
100000128243
Created by
admin on Mon Mar 31 18:00:39 GMT 2025 , Edited by admin on Mon Mar 31 18:00:39 GMT 2025
|
PRIMARY | |||
|
211-836-2
Created by
admin on Mon Mar 31 18:00:39 GMT 2025 , Edited by admin on Mon Mar 31 18:00:39 GMT 2025
|
PRIMARY | |||
|
INDOLE-3-CARBINOL
Created by
admin on Mon Mar 31 18:00:39 GMT 2025 , Edited by admin on Mon Mar 31 18:00:39 GMT 2025
|
PRIMARY | |||
|
C11E72455F
Created by
admin on Mon Mar 31 18:00:39 GMT 2025 , Edited by admin on Mon Mar 31 18:00:39 GMT 2025
|
PRIMARY | |||
|
700-06-1
Created by
admin on Mon Mar 31 18:00:39 GMT 2025 , Edited by admin on Mon Mar 31 18:00:39 GMT 2025
|
PRIMARY | |||
|
DB12881
Created by
admin on Mon Mar 31 18:00:39 GMT 2025 , Edited by admin on Mon Mar 31 18:00:39 GMT 2025
|
PRIMARY | |||
|
DTXSID7031458
Created by
admin on Mon Mar 31 18:00:39 GMT 2025 , Edited by admin on Mon Mar 31 18:00:39 GMT 2025
|
PRIMARY | |||
|
C11E72455F
Created by
admin on Mon Mar 31 18:00:39 GMT 2025 , Edited by admin on Mon Mar 31 18:00:39 GMT 2025
|
PRIMARY | |||
|
24814
Created by
admin on Mon Mar 31 18:00:39 GMT 2025 , Edited by admin on Mon Mar 31 18:00:39 GMT 2025
|
PRIMARY | |||
|
C1135
Created by
admin on Mon Mar 31 18:00:39 GMT 2025 , Edited by admin on Mon Mar 31 18:00:39 GMT 2025
|
PRIMARY | |||
|
2598119
Created by
admin on Mon Mar 31 18:00:39 GMT 2025 , Edited by admin on Mon Mar 31 18:00:39 GMT 2025
|
PRIMARY | |||
|
3712
Created by
admin on Mon Mar 31 18:00:39 GMT 2025 , Edited by admin on Mon Mar 31 18:00:39 GMT 2025
|
PRIMARY | |||
|
SUB35050
Created by
admin on Mon Mar 31 18:00:39 GMT 2025 , Edited by admin on Mon Mar 31 18:00:39 GMT 2025
|
PRIMARY | |||
|
525801
Created by
admin on Mon Mar 31 18:00:39 GMT 2025 , Edited by admin on Mon Mar 31 18:00:39 GMT 2025
|
PRIMARY | |||
|
C016517
Created by
admin on Mon Mar 31 18:00:39 GMT 2025 , Edited by admin on Mon Mar 31 18:00:39 GMT 2025
|
PRIMARY |
SUBSTANCE RECORD